Candriam S.C.A. Increases Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Candriam S.C.A. grew its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 14.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,071,825 shares of the company's stock after acquiring an additional 131,385 shares during the period. Candriam S.C.A. owned 1.24% of IDEAYA Biosciences worth $27,546,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in IDYA. Raymond James Financial Inc. acquired a new stake in shares of IDEAYA Biosciences during the 4th quarter worth approximately $431,000. Arizona State Retirement System boosted its stake in IDEAYA Biosciences by 12.4% during the fourth quarter. Arizona State Retirement System now owns 22,049 shares of the company's stock worth $567,000 after acquiring an additional 2,436 shares in the last quarter. Aigen Investment Management LP acquired a new stake in IDEAYA Biosciences in the fourth quarter worth $280,000. Assetmark Inc. increased its stake in IDEAYA Biosciences by 2.5% in the fourth quarter. Assetmark Inc. now owns 45,269 shares of the company's stock valued at $1,163,000 after purchasing an additional 1,084 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in IDEAYA Biosciences by 8.9% in the fourth quarter. Victory Capital Management Inc. now owns 341,063 shares of the company's stock valued at $8,765,000 after purchasing an additional 27,806 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IDYA has been the subject of several research reports. Stephens restated an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Wedbush reiterated an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $53.58.

Remove Ads

IDEAYA Biosciences Stock Performance

IDYA traded down $0.92 during mid-day trading on Monday, reaching $17.54. 903,400 shares of the stock were exchanged, compared to its average volume of 888,080. IDEAYA Biosciences, Inc. has a 1 year low of $17.32 and a 1 year high of $46.40. The stock has a market capitalization of $1.54 billion, a PE ratio of -5.32 and a beta of 0.76. The company has a 50 day moving average price of $22.66 and a two-hundred day moving average price of $27.89.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. Sell-side analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.